The main treatment is supportive and symptomatic treatment by fluid-replacement therapy. Discovery of a new antiviral drug for dengue is the best hope for treatment.
Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA) CEO and managing director David Foster to get the short end of the long story on the company’s latest news.
The company announced that it will cease development of Mosnodenvir, a drug candidate designed to be the first anti-viral treatment for dengue. It is unclear if another developer will license the ...
The drug, produced by the laboratory Takeda, targets “dengue virus 2” and protects ... and Medical Technology (Anmat) approved the treatment which is already available at private vaccination ...